| Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and … G Mazzaschi, D Madeddu, A Falco, G Bocchialini, M Goldoni, F Sogni, ... Clinical cancer research 24 (2), 407-419, 2018 | 227 | 2018 |
| Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer A Leonetti, B Wever, G Mazzaschi, YG Assaraf, C Rolfo, F Quaini, M Tiseo, ... Drug Resistance Updates 46, 100644, 2019 | 169 | 2019 |
| First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ... European Journal of Cancer 130, 155-167, 2020 | 111 | 2020 |
| The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC G Mazzaschi, F Facchinetti, G Missale, D Canetti, D Madeddu, A Zecca, ... Lung cancer 127, 153-163, 2019 | 104 | 2019 |
| Soluble PD-L1 and circulating CD8+ PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients G Mazzaschi, R Minari, A Zecca, A Cavazzoni, V Ferri, C Mori, A Squadrilli, ... Lung Cancer 148, 1-11, 2020 | 75 | 2020 |
| Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab F Facchinetti, M Veneziani, S Buti, F Gelsomino, A Squadrilli, P Bordi, ... Immunotherapy 10 (8), 681-694, 2018 | 35 | 2018 |
| Small cell lung cancer transformation as a resistance mechanism to osimertinib in epidermal growth factor receptor-mutated lung adenocarcinoma: case report and literature review A Leonetti, R Minari, G Mazzaschi, L Gnetti, S La Monica, R Alfieri, ... Frontiers in Oncology 11, 642190, 2021 | 33 | 2021 |
| Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism C Fumarola, D Cretella, S La Monica, MA Bonelli, R Alfieri, C Caffarra, ... Oncotarget 8 (54), 91841, 2017 | 31 | 2017 |
| Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC G Mazzaschi, G Milanese, P Pagano, D Madeddu, L Gnetti, F Trentini, ... Lung Cancer 144, 30-39, 2020 | 29 | 2020 |
| Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy S Buti, M Bersanelli, F Perrone, S Bracarda, M Di Maio, R Giusti, O Nigro, ... European Journal of Cancer 150, 224-231, 2021 | 27 | 2021 |
| Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With … R Minari, G Mazzaschi, P Bordi, L Gnetti, G Alberti, A Altimari, E Gruppioni, ... Clinical Lung Cancer 21 (5), e464-e473, 2020 | 26 | 2020 |
| Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer G Bocchialini, C Lagrasta, D Madeddu, G Mazzaschi, D Marturano, ... European Journal of Cardio-Thoracic Surgery 58 (3), 619-628, 2020 | 19 | 2020 |
| Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors M Savi, C Frati, S Cavalli, G Graiani, S Galati, A Buschini, D Madeddu, ... Pharmacological Research 127, 15-25, 2018 | 17 | 2018 |
| PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort D Santini, T Zeppola, M Russano, F Citarella, C Anesi, S Buti, M Tucci, ... Journal of Translational Medicine 19 (1), 270, 2021 | 14 | 2021 |
| Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer G Armani, D Madeddu, G Mazzaschi, G Bocchialini, F Sogni, C Frati, ... European Journal of Cardio-Thoracic Surgery 53 (6), 1205-1213, 2018 | 13 | 2018 |
| Modulating tumor microenvironment: a review on STK11 immune properties and predictive vs prognostic role for non-small-cell lung cancer immunotherapy G Mazzaschi, A Leonetti, R Minari, L Gnetti, F Quaini, M Tiseo, ... Current Treatment Options in Oncology 22, 1-25, 2021 | 11 | 2021 |
| PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors R Minari, F Bonatti, G Mazzaschi, A Dodi, F Facchinetti, F Gelsomino, ... Tumori Journal 108 (1), 47-55, 2022 | 10 | 2022 |
| Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs A Leonetti, M Capula, R Minari, G Mazzaschi, A Gregori, B El Hassouni, ... Cells 10 (6), 1520, 2021 | 10 | 2021 |
| Cytoreductive nephrectomy in the era of targeted-and immuno-therapy for metastatic renal cell carcinoma: an elusive issue? A systematic review of the literature G Mazzaschi, F Quaini, M Bersanelli, S Buti Critical Reviews in Oncology/Hematology 160, 103293, 2021 | 8 | 2021 |
| Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report G Mazzaschi, C Tommasi, E Pietri, L Corcione, A De Giorgi, P Bini, S Bui Clinical Case Reports 9 (3), 1334-1338, 2021 | 8 | 2021 |
